Ani Pharmaceuticals (ANIP) EPS (Weighted Average and Diluted) (2010 - 2026)

Ani Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 17 years of filings, most recently posting $1.28 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.28, up 85.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.94 (up 410.24% YoY), and the FY2025 annual result was $3.32, up 419.23% from the prior year.
• EPS (Weighted Average and Diluted) came in at $1.28 for Q1 2026 at Ani Pharmaceuticals, up from $1.17 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.28 in Q1 2026 to a low of -$1.27 in Q1 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.06 (2023), against an average of $0.07.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 12800.0% in 2022 and jumped 1266.67% in 2024, its largest moves.
• Ani Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.29 in 2022, then jumped by 106.9% to $0.02 in 2023, then slumped by 2850.0% to -$0.55 in 2024, then surged by 312.73% to $1.17 in 2025, then gained by 9.4% to $1.28 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.28 (Q1 2026), $1.17 (Q4 2025), and $1.13 (Q3 2025), per Business Quant data.